Hiroshi Sakai

Hiroshi Sakai

Auto-generated profile, based on publicly available information

Hiroshi Sakai

Division of Integrative Pathophysiology, Proteo-Science Center, Ehime University, Ehime 791-0295, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Molecular Cell
Verified
Journal Article
Closed access
LGLorenzo Giordani
Lorenzo Giordani
GHGary J. He
Gary J. He
ENElisa Negroni
Elisa Negroni
HSHiroshi Sakai
Hiroshi Sakai
JLJustin Y.C. Law
Justin Y.C. Law
FGFabien Le Grand
Fabien Le Grand

1 March 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
ACAurélie Chiche
Aurélie Chiche
IRIsabelle Le Roux
Isabelle Le Roux
MJMathieu von Joest
Mathieu von Joest
HSHiroshi Sakai
Hiroshi Sakai
SASabela Búa Aguín
Sabela Búa Aguín
HLHan Li
Han Li

11 June 2015 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
LSLenka Skalska
Lenka Skalska
RSRobert Stojnic
Robert Stojnic
JLJinghua Li
Jinghua Li
BFBettina Fischer
Bettina Fischer
GCGustavo Cerda‐Moya
Gustavo Cerda‐Moya
SBSarah J Bray
Sarah J Bray

24 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHidetoshi Sakurai
Hidetoshi Sakurai
YSYasuko Sakaguchi
Yasuko Sakaguchi
ESEmi Shoji
Emi Shoji
TNTokiko Nishino
Tokiko Nishino
IMIzumi Maki
Izumi Maki
ASAtsuko Sehara-Fujisawa
Atsuko Sehara-Fujisawa
Induced pluripotent stem (iPS) cells are generated from adult somatic cells by transduction of defined factors. Given their unlimited proliferation and differentiation potential, iPS cells represent promising sources for cell therapy and tools for research and drug discovery. However, systems for the directional differentiation of iPS cells toward paraxial mesodermal lineages have not been reported. In the present study, we established a protocol for the differentiation of mouse iPS cells into paraxial mesodermal lineages in serum-free culture. The protocol was dependent on Activin signaling in addition to BMP and Wnt signaling which were previously shown to be effective for mouse ES cell differentiation. Independently of the cell origin, the number of transgenes, or the type of vectors used to generate iPS cells, the use of serum-free monolayer culture stimulated with a combination of BMP4, Activin A, and LiCl enabled preferential promotion of mouse iPS cells to a PDGFR-α+/Flk-1− population, which represents a paraxial mesodermal lineage. The mouse iPS cell-derived paraxial mesodermal cells exhibited differentiation potential into osteogenic, chondrogenic, and myogenic cells both in vitro and in vivo and contributed to muscle regeneration. Moreover, purification of the PDGFR-α+/KDR− population after differentiation allowed enrichment of human iPS cell populations with paraxial mesodermal characteristics. The resultant PDGFR-α+/KDR− population derived from human iPS cells specifically exhibited osteogenic, chondrogenic, and myogenic differentiation potential in vitro, implying generation of paraxial mesodermal progenitors similar to mouse iPS cell-derived progenitors. These findings highlight the potential of protocols based on the serum-free, stepwise induction and purification of paraxial mesodermal cell lineages for use in stem cell therapies to treat diseased bone, cartilage, and muscle.

1 April 2021 in iScience
Verified
Journal Article
Open access
ISIori Sakakibara
Iori Sakakibara
YYYuta Yanagihara
Yuta Yanagihara
KHKoichi Himori
Koichi Himori
Takashi YamadaTakashi Yamada
Takashi Yamada
HSHiroshi Sakai
Hiroshi Sakai
YIYuuki Imai
Yuuki Imai
Androgens have a robust effect on skeletal muscles to increase muscle mass and strength. The molecular mechanism of androgen/androgen receptor (AR) action on muscle strength is still not well known, especially for the regulation of sarcomeric genes. In this study, we generated androgen-induced hypertrophic model mice, myofiber-specific androgen receptor knockout (cARKO) mice supplemented with dihydrotestosterone (DHT). DHT treatment increased grip strength in control mice but not in cARKO mice. Transcriptome analysis by RNA-seq, using skeletal muscles obtained from control and cARKO mice treated with or without DHT, identified a fast-type muscle-specific novel splicing variant of Myosin light-chain kinase 4 (Mylk4) as a target of AR in skeletal muscles. Mylk4 knockout mice exhibited decreased maximum isometric torque of plantar flexion and passive stiffness of myofibers due to reduced phosphorylation of Myomesin 1 protein. This study suggests that androgen-induced skeletal muscle strength is mediated with Mylk4 and Myomesin 1 axis.

1 March 2019 in Stem Cell Reports
Verified
Journal Article
Open access
MGMattia Francesco Maria Gerli
Mattia Francesco Maria Gerli
LMLouise Anne Moyle
Louise Anne Moyle
SBSara Benedetti
Sara Benedetti
GFGiuliana Ferrari
Giuliana Ferrari
EUEkin Ucuncu
Ekin Ucuncu
FTFrancesco Saverio Tedesco
Francesco Saverio Tedesco
Satellite cells are responsible for skeletal muscle regeneration. Upon activation, they proliferate as transient amplifying myoblasts, most of which fuse into regenerating myofibers. Despite their remarkable differentiation potential, these cells have limited migration capacity, which curtails clinical use for widespread forms of muscular dystrophy. Conversely, skeletal muscle perivascular cells have less myogenic potential but better migration capacity than satellite cells. Here we show that modulation of Notch and PDGF pathways, involved in developmental specification of pericytes, induces perivascular cell features in adult mouse and human satellite cell-derived myoblasts. DLL4 and PDGF-BB-treated cells express markers of perivascular cells and associate with endothelial networks while also upregulating markers of satellite cell self-renewal. Moreover, treated cells acquire trans-endothelial migration ability while remaining capable of engrafting skeletal muscle upon intramuscular transplantation. These results extend our understanding of muscle stem cell fate plasticity and provide a druggable pathway with clinical relevance for muscle cell therapy.